Wei‐Xiang Qi
Macau University of Science and Technology(MO)Henan University of Science and Technology(CN)Shanghai Jiao Tong University(CN)Ruijin Hospital(CN)Shanghai Genon Biological Products (China)(CN)People's Liberation Army No. 150 Hospital(CN)Tongren Hospital(CN)Xijing Hospital(CN)Southeast University(CN)Air Force Medical University(CN)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Esophageal Cancer Research and Treatment, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)(2020)311 cited
- → Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials(2013)201 cited
- → Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis(2014)123 cited
- → Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis(2013)115 cited
- → Risk of venous thromboembolic events associated with VEGFR‐TKIs: A systematic review and meta‐analysis(2012)100 cited
- → Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis(2012)90 cited